Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1056-1071

  Yamazaki, Yuri ^a,b   Tanaka, Koji ^b   Nicholson, Benjamin ^c   Deyanat Yazdi, Gordafaried ^c   Potts, Barbara ^c   Yoshida, Tomoko ^b   Oda, Akiko ^b   Kitagawa, Takayoshi ^b   Orikasa, Sumie ^b   Kiso, Yoshiaki ^b   Yasui, Hiroyuki ^b   Akamatsu, Miki ^d   Chinen, Takumi ^e   Usui, Takeo ^e   Shinozaki, Yuki ^a   Yakushiji, Fumika ^a   Miller, Brian R ^c   Neuteboom, Saskia ^c   Palladino, Michael ^c   Kanoh, Kaneo ^f   Lloyd, George Kenneth ^c   Hayashi, Yoshio ^a,b   more..

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c Nereus Pharmaceuticals Inc   (United States)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f MARINE BIOTECHNOLOGY INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 ((5 TERT BUTYL 1H IMIDAZOL 4 YL)METHYLENE) 6 (2,5 DIFLUOROBENZYLIDENE)PIPERAZINE 2,5 DIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2 BROMOPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2 FLUOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2 METHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2 METHYLPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2,3 DICHLOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2,4 DIMETHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2,5 DIMETHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2,6 DIMETHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (2,6 DIMETHYLPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (3 BROMOPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (3 CHLOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (3 FLUOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (3 METHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (3 METHYLPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (3,5 DIMETHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (4 CHLOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (4 FLUOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (4 METHOXYPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE] 6 [1 (4 METHYLPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 [1 [5 (TERT BUTYL) 1H 4 IMIDAZOLYL]METHYLIDENE]6 [1 (2 CHLOROPHENYL)METHYLIDENE] 2,5 PIPERAZINEDIONE; 3 BENZYLIDENE 6 [(5 BUTYL 1H IMIDAZOL 4 YL)METHYLENE]PIPERAZINE 2,5 DIONE; 3 BENZYLIDENE 6 [(5 ISOPROPYL 1H IMIDAZOL 4 YL]METHYLENE)PIPERAZINE 2 DIONE; 3 BENZYLIDENE 6 [(5 METHYL 1H IMIDAZOL 4 YL)METHYLENE]PIPERAZINE 2,5 DIONE; 3 BENZYLIDENE 6 [(5 PROPYL 1H IMIDAZOL 4 YL)METHYLENE]PIPERAZINE 2,5 DIONE; 3 BENZYLIDENE 6 [(5 SEC BUTYL 1H IMIDAZOL 4 YL)METHYLENE]PIPERAZINE 2,5 DIONE; CYTOTOXIC AGENT; PIPERAZINEDIONE; PLINABULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DEPOLYMERIZATION; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PROSTATE CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CRYSTALLOGRAPHY, X-RAY; DIKETOPIPERAZINES; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STEREOISOMERISM; TUBULIN MODULATORS;

EID: 84863158929     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2009088     Document Type: Article

References (64)

1. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: A dynamic field of cancer therapeutics Nat. Rev. Drug Discovery 2010, 9, 790-803
2. Shi, Q.; Chen, K.; Morris-Natschke, S. L.; Lee, K. H. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents Curr. Pharm. Des. 1998, 4, 219-248 (Pubitemid 28277446)
3. Suffness, M.; Wall, M. E. Taxol: Science and Applications; Suffness, M., Ed.; CRC Press: Boca Raton, FL, 1995; pp 3-25.
4. Mekhail, T. M.; Markman, M. Paclitaxel in cancer therapy Expert Opin. Pharmacother. 2002, 3, 755-766 (Pubitemid 34649705)
5. Rowinsky, E. K.; Donehower, R. C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics Pharmacol. Ther. 1991, 52, 35-84
6. Volm, M. Multidrug resistance and its reversal Anticancer Res. 1998, 18, 2095-2917
7. Ferlini, C.; Ojima, I.; Distefano, M.; Gallo, D.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Mancuso, S.; Scambia, G. Second generation taxanes: From the natural framework to the challenge of drug resistance Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 133-138 (Pubitemid 36230884)
8. Kavallaris, M. Microtubules and resistance to tubulin-binding agents Nat. Rev. Cancer 2010, 10, 194-204
9. Hastie, S. B. Interactions of colchicines with tubulin Pharmacol. Ther. 1991, 51, 377-401
10. Eigsti, O. J.; Dustin, P., Jr. Colchicine in Agriculture, Medicine, Biology, and Chemistry; Iowa State College Press: Ames, IA, 1955; Chapter 1.
11. Kelly, M.; Hartwell, J. L. The biological effects and the chemical composition of podophyllin J. Natl. Cancer Inst. 1954, 14, 967-1010
12. Cortese, F.; Bhattacharyya, B.; Wolff, J. Podophyllotoxin as a probe for the colchicines binding site of tubulin J. Biol. Chem. 1977, 521, 1134-1140 (Pubitemid 8071267)
13. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 1989, 28, 6984-6991 (Pubitemid 19219888)
14. Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) J. Med. Chem. 1995, 38, 1666-1672
15. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells Mol. Pharmacol. 1998, 53, 62-76 (Pubitemid 28068373)
16. Chang, Z.; Sitachitta, N.; Rossi, J. V.; Roberts, M. A.; Flatt, P. M.; Jia, J.; Sherman, D. H.; Gerwick, W. H. Biosynthetic pathway and gene cluster analysis of curacin A, an antitubulin natural product from the tropical marine cyanobacterium Lyngbya majuscula J. Nat. Prod. 2004, 67, 1356-1367 (Pubitemid 39145643)
17. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R. L.; Chaplin, D. J.; Hill, S. A. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res. 2002, 62, 7247-7253 (Pubitemid 36025246)
18. Micheletti, G.; Poli, M.; Borsotti, P.; Martinelli, M.; Imberti, B.; Taraboletti, G.; Giavazzi, R. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent Cancer Res. 2003, 63, 1534-1537 (Pubitemid 36373640)
19. Ohsumi, K.; Hatanaka, T.; Nakagawa, R.; Fukuda, Y.; Morinaga, Y.; Suga, Y.; Nihei, Y.; Ohishi, K.; Akiyama, Y.; Tsuji, T. Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins Anti-Cancer Drug Des. 1999, 14, 539-548 (Pubitemid 30258972)
20. Hori, K.; Saito, S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis Br. J. Cancer 2003, 89, 1334-1344 (Pubitemid 37363426)
21. Koyanagi, N.; Nagasu, T.; Fujita, F.; Watanabe, T.; Tsukahara, K.; Funahashi, Y.; Fujita, M.; Taguchi, T.; Yoshino, H.; Kitoh, K. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors Cancer Res. 1994, 54, 1702-1706 (Pubitemid 24116173)
22. Segreti, J. A.; Polakowski, J. S.; Koch, K. A.; Marsh, K. C.; Bauch, J. L.; Rosenberg, S. H.; Sham, H. L.; Cox, B. F.; Reinhart, G. A. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: An in vivo rat regional hemodynamic study Cancer Chemother. Pharmacol. 2004, 54, 273-281 (Pubitemid 39141745)
23. Wang, R. W-J.; Rebhun, L. I.; Kupchan, S. M. Antimitotic and antitubulin activity of the tumor inhibitor steganacin Cancer Res. 1977, 37, 3071-3079 (Pubitemid 8169960)
24. Hoebeke, J.; Nijen, G. V.; Brabander, M. D. Interaction of oncodazole (R 17934), a new anti-tumoral drug, with rat brain tubulin Biochem. Biophys. Res. Commun. 1976, 69, 319-324
25. Samson, F.; Donoso, J. A.; Heller-Bettinger, I.; Watsonand, D.; Himes, R. H. Nocodazole action on tubulin assembly, axonal ultrastructure and fast axoplasmic transport J. Pharmacol. Exp. Ther. 1979, 208, 411-417 (Pubitemid 9199963)
26. Baguley, B. C.; Holdaway, K. M.; Thomsen, L. L.; Zhuang, L.; Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism Eur. J. Cancer 1991, 27, 482-487
27. Hill, S. A.; Lonergan, S. J.; Denekamp, J.; Chaplin, D. J. Vinca alkaloids: Antivascular effects in a murine tumor Eur. J. Cancer 1993, 29A, 1320-1324 (Pubitemid 23169906)
28. Chaplin, D. J.; Pettit, G. R.; Parkins, C. S.; Hill, S. A. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents Br. J. Cancer 1996, 74 (Suppl. XXVII) S86-S88
29. Nihei, Y.; Suzuki, M.; Okano, A.; Tsuji, T.; Akiyama, Y.; Tsuruo, T.; Saito, S.; Hori, K.; Sato, Y. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy Jpn. J. Cancer. Res. 1999, 90, 1387-1396
30. Daenen, L. G. M.; Roodhart, J. M. L.; Shaked, Y.; Voest, E. E. Vascular disrupting agents (VDAs) in anticancer therapy Curr. Clin. Pharmacol. 2010, 5, 178-185
31. Kanoh, K.; Kohno, S.; Asari, T.; Harada, T.; Katada, J.; Muramatsu, M.; Kawashima, H.; Sekiya, H.; Uno, I. (-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus ustus Bioorg. Med. Chem. Lett. 1997, 7, 2847-2852 (Pubitemid 27497724)
32. Kanoh, K.; Kohno, S.; Katada, J.; Takahashi, J.; Uno, I. (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization J. Antibiot. 1999, 52, 134-141 (Pubitemid 29137582)
33. Kanoh, K.; Kohno, S.; Katada, J.; Hayashi, Y.; Muramatsu, M.; Uno, I. Antitumor activity of phenylahistin in vitro and in vivo Biosci., Biotechnol., Biochem. 1999, 63, 1130-1133 (Pubitemid 129562744)
34. Fenical, W.; Jensen, P. R.; Cheng, X. C. Halimide, a cytotoxic marine natural product, derivatives thereof, and therapeutic use in inhibition of proliferation. PCT Int. Appl. WO 9948889, 1999.
35. Fenical, W.; Jensen, P. R.; Cheng, X. C. U.S. patent US6069146, 2000.
36. Kanoh, K.; Kohno, S.; Katada, J.; Takahashi, J.; Uno, I.; Hayashi, Y. Synthesis and biological activities of phenylahistin derivatives Bioorg. Med. Chem. 1999, 7, 1451-1457 (Pubitemid 29292385)
37. Hayashi, Y.; Orikasa, S.; Tanaka, K.; Kanoh, K.; Kiso, Y. Total synthesis of anti-microtubule diketopiperazine derivatives: Phenylahistin and aurantiamine J. Org. Chem. 2000, 65, 8402-8405
38. Kanzaki, H.; Yanagisawa, S.; Kanoh, K.; Nitoda, T. A novel potent cell cycle inhibitor dehydrophenylahistin: Enzymatic synthesis and inhibitory activity toward sea urchin embryo J. Antibiot. 2002, 55, 1042-1047 (Pubitemid 36097890)
39. Nicholson, B.; Lloyd, G. K.; Miller, B. R.; Palladino, M. A.; Kiso, Y.; Hayashi, Y.; Neulteboom, S. T. C. NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent Anti-Cancer Drugs 2006, 17, 25-31
40. Mita, M. M.; Spear, M. A.; Yee, L. K.; Mita, A. C.; Heath, E. I.; Papadopoulos, K. P.; Federico, K. C.; Reich, S. D; Romero, O.; Malburg, L.; Pilat, M.; Lloyd, G. K.; Neuteboom, S. T. C.; Cropp, G.; Ashton, E.; LoRusso, P. M. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas Clin. Cancer Res. 2010, 16, 5892-5899
41. Ferrer, E.; Bolós, J.; Castañer, R. Plinabulin Drugs Future 2010, 35, 11-15
42. Suzuki, M.; Iwasaki, T.; Miyoshi, M.; Okumura, K.; Matsumoto, K. Synthesis of amino acids and related compounds. 6. New convenient synthesis of α-C-acylamino acids and α-amino ketones J. Org. Chem. 1973, 38, 3571-3575
43. Makino, K.; Okamoto, N.; Hara, O.; Hamada, Y. Efficient enantioselective synthesis of (2 R,3 R)- and (2 S,3 S)-3-hydroxyleucines and their diastereomers through dynamic kinetic resolution Tetrahedron: Asymmetry 2001, 12, 1757-1762 (Pubitemid 32757112)
44. Weitman, M.; Lerman, L.; Cohen, S.; Nudelman, A.; Major, D. T.; Gottlieb, H. E. Facile structural elucidation of imidazoles and oxazoles based on NMR spectroscopy and quantum mechanical calculations Tetrahedron 2010, 66, 1465-1471
45. Bredereck, H.; Theilig, G. Untersuchungen in der oxazolreihe und umwandlungen von oxazolen in imidazole mittels formamids (formamid-reaktionen, II. mitteil.) Chem. Ber. 1952, 86, 88-96
46. Loughlin, W. A.; Marshall, R. L.; Carreiro, A.; Elson, K. E. Solution-phase combinatorial synthesis and evaluation of piperazine-2,5-dione derivatives Bioorg. Med. Chem. Lett. 2000, 10, 91-94 (Pubitemid 30055432)
47. Folkes, A.; Roe, M. B.; Sohal, S.; Golec, J.; Faint, R.; Brooks, T.; Charlton, P. Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1 Bioorg. Med. Chem. Lett. 2001, 11, 2589-2592 (Pubitemid 32823362)
48. Gallina, C.; Liberatori, A. Condensation of 1,4-diacetylpiperazine-2,5- dione with aldehydes Tetrahedron 1974, 30, 667-673
49. Watanabe, T.; Ishikawa, T. Mild air-oxidation of 1,3-dicarbonyl compounds with cesium salts: Novel α-hydroxylation accompanied by partial hydrolysis of malonate derivatives Tetrahedron Lett. 1999, 40, 7795-7798 (Pubitemid 29487923)
50. Andreu, J. M.; Perez-Ramirez, B.; Gorbunoff, M. J.; Ayala, D.; Timasheff, S. N. Role of the colchicine ring A and its methoxy groups in the binding to tubulin and microtubule inhibition Biochemistry 1998, 37, 8356-8368 (Pubitemid 28275454)
51. Nam, N.-H.; Kim, Y.; You, Y.-J.; Hong, D.-H.; Kim, H.-M.; Ahn, B.-Z. Synthesis and anti-tumor activity of novel combretastatins: Combretocyclopentenones and related analogues Bioorg. Med. Chem. Lett. 2002, 12, 1955-1958 (Pubitemid 34756457)
52. Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry ChemBioChem 2004, 5, 637-643 (Pubitemid 39257085)
53. Olsen, J. A.; Banner, D. W.; Seiler, P.; Obst-Sander, U.; D'Arcy, A.; Stihle, M.; Müller, K.; Diederich, F. A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: Evidence for C-F•••C=O interactions Angew. Chem., Int. Ed. 2003, 42, 2507-2511 (Pubitemid 36753422)
54. α- C=O comprise a favorable C-F environment and interactions of CF with electrophiles ChemBioChem 2004, 5, 666-675 (Pubitemid 39257089)
55. Brossi, A.; Boye, O.; Muzaffar, A.; Yeh, H. J. C.; Toome, V.; Wegrzynski, B.; George, C. a S,7 S -Absolute configuration of natural (-)-colchicine and allo-congeners FEBS Lett. 1990, 262, 5-7 (Pubitemid 20104246)
56. Yeh, H. J. C.; Chrzanowska, M.; Brossi, A. The importance of the phenyl-tropolone 'a S ' configuration in colchicine's binding to tubulin FEBS Lett. 1988, 229, 82-86 (Pubitemid 18058752)
57. Zhang, S.-X.; Feng, J.; Kuo, S.-C.; Brossi, A.; Hamel, E.; Tropsha, A.; Lee, K.-H. Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis J. Med. Chem. 2000, 43, 167-76 (Pubitemid 30078148)
58. Kim, S.; Min, S. Y.; Lee, S. K.; Cho, W.-J. Comparative molecular field analysis study of stilbene derivatives active against A549 lung carcinoma Chem. Pharm. Bull. 2003, 51, 516-521 (Pubitemid 41656802)
59. Combes, S.; Barbier, P.; Douillard, S.; McLeer-Florin, A.; Bourgarel-Rey, V.; Pierson, J.-T.; Fedorov, A. Y.; Finet, J.-P.; Boutonnat, J.; Peyrot, V. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2 J. Med. Chem. 2011, 54, 3153-3162
60. Yamazaki, Y.; Kohno, K.; Yasui, H.; Kiso, Y.; Akamatsu, M.; Nicholson, B.; Deyanat-Yazdi, G.; Neuteboom, S.; Potts, B.; Lloyd, G. K.; Hayashi, Y. Tubulin photoaffinity labeling with biotin-tagged derivatives of potent diketopiperazine antimicrotubule agents ChemBioChem 2008, 9, 3074-3081
61. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 1988, 110, 5959-5967
62. Yamazaki, Y.; Kido, Y.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole Bioorg. Med. Chem. 2011, 19, 595-692
63. Mitchell, S. S.; Nicholson, B.; Teisan, S.; Lam, K. S.; Potts, B. C. M. Aureoverticillactum, a novel 22-atom macrocyclic lactum from the marine actinomycete Streptomyces aureoverticillatus J. Nat. Prod. 2004, 67, 1400-1402 (Pubitemid 39145651)
64. Castoldi, M.; Popov, A. V. Purification of brain tubulin through two cycles of polymerization-depolymerization in a high-molarity buffer Protein Expression Purif. 2003, 32, 83-88 (Pubitemid 37436140)